<![CDATA[Background: Metastatic bone disease (MBD) is a frequent complication in advanced cancer, often resulting in pain, limited mobility, and reduced QoL. Bisphosphonates are effective in minimizing skeletal-related events by suppressing osteoclast activity. Objective: To assess the impact of bisphosphonate therapy on serum calcium levels and QoL in patients with metastatic bone disease. Methods: A retrospective cohort study was conducted involving 228 MBD patients treated at Dr. Soetomo General Hospital from 2015 to 2020. Surgical eligibility was determined using the Abdurrahman Score. Pre- and post-treatment data on serum calcium levels and Karnofsky Scores were collected and analyzed using paired t-tests. Results: In the surgical group, the mean Karnofsky Score improved from 46.67 ± 12.69 to 77.67 ± 9.35 (p < 0.001), while serum calcium levels decreased from 10.1 ± 1.20 to 7.3 ± 1.01 (p < 0.001). In the non-surgical group, Karnofsky Scores increased from 36.67 ± 12.22 to 49.35 ± 13.15, and calcium levels declined from 10.2 ± 1.18 to 7.6 ± 1.33 (both p < 0.001). Conclusion: Bisphosphonate therapy significantly enhances QoL and reduces serum calcium levels in patients with metastatic bone disease. The combination of surgical management and bisphosphonate therapy yields superior functional outcomes compared to non-surgical treatment.]]>
Copyrights © 2026
